AI Engineer, Patent owner of Artificial Intelligence-assisted methodology for Medical Discovery. Tweets are mine/not medical advice or endorsements.
Joined May 2009
- Tweets2.4K
- Following3K
- Followers5K
- Likes3.7K
Efthymios Kalafatis retweeted
Today, in collaboration with Anthropic, we’re excited to share rapid initial progress towards an antibody treatment for food allergy, which affects over 200 million people worldwide, discovered with the help of Claude.
At Divergence Labs, we believe that AI can unlock the next generation of antibody therapeutics with more effective mechanisms than before. Such mechanisms are urgently needed in food allergy, which involve overcoming one of the tightest affinity protein pairs in immunology, IgE and its receptor FcεRI, on mast cells.
Treatment with Xolair—the only approved antibody for food allergy—sequesters circulating IgE, but mast cells remain sensitized for weeks to months due to the extraordinarily slow dissociation of IgE from FcεRI.
We envision a treatment that actively pulls IgE off of FcεRI, without waiting for natural dissociation. Like picking a lock, this requires the right combination of geometry and force.
Our research team, working with Claude, ideated on mechanisms to accomplish this disruption, and converged on an antibody format with two arms with different functions and epitopes. Within one month, we designed, synthesized, and experimentally confirmed the biophysical function of the two arms, which we are now assembling into full therapeutic formats.
Efthymios Kalafatis retweeted
I just spoke to an 8th-semester medical student.
Not a SINGLE class on ME/CFS.
A neurological disease affecting potentially 70 MILLION people worldwide, yet future doctors aren’t even taught about it.
This isn’t just an educational gap. It’s a medical scandal.
Efthymios Kalafatis retweeted
BREAKING: The U.S. government, Google, Meta & Zuckerberg-backed @biohub are launching a $1.8B push to build the data layer for AI biology.
The goal is to create the largest open, AI-ready biological dataset ever assembled, giving models the data needed to better predict how biology works & ultimately help treat disease.
The coalition is massive:
› Biohub committed $500M
› DOE is investing $500M+ across measurement, modeling & compute
› NIH is bringing $500M+ of federally funded datasets & repositories
› Meta, Google DeepMind & @IsomorphicLabs are jointly investing another $300M
This is effectively an infrastructure buildout for AI biology.
Instead of just building bigger models, they’re attacking one of the biggest bottlenecks in biology AI today, generating standardized, high-quality biological data at massive scale & making it openly available to researchers.
$1.8B committed to turning biology into something AI can increasingly model, predict & engineer.
Efthymios Kalafatis retweeted
Support link is artizen.fund/index/p/open-po…
Project link is pots.erinmagennis.com
Efthymios Kalafatis retweeted
Hello @melindagates,
I’m reaching out to draw your attention to myalgic encephalomyelitis (ME/CFS), a severe neuroimmune disease that remains dramatically underfunded and affects women disproportionately.
In its severe forms, patients can remain bedridden for years, unable to work or leave their homes, and sometimes unable even to wash themselves or tolerate light, noise, or a simple conversation. Some become completely dependent on their families while remaining fully aware and intellectually intact.
Despite millions of people being affected worldwide, and the growing urgency created by Long COVID, there is still no curative treatment.
Your commitment to women and to the most vulnerable could have an enormous impact here. Financial support for ME/CFS research could accelerate the discovery of biomarkers and, above all, treatments for patients who have sometimes been waiting for decades.
Thank you simply for taking the time to look at this disease and at those who are still living almost invisibly in the eyes of the world.
Efthymios Kalafatis retweeted
1) Unfortunately, another negative result for immunoadsorption for Long Covid.
A small trial that focused only on patients with elevated levels of antibodies against β1/β2-adrenergic and/or M3/M4-muscarinic acetylcholine receptors found no improvement in objective outcomes.
Efthymios Kalafatis retweeted
Less protein, more lifespan!
A comprehensive review of the merits of protein restriction for healthy aging
A flip from the proteinmaxxing craze
"cell.com/cell-press-blue/ful…
Efthymios Kalafatis retweeted
I've made a genetics app, which is designed so that #MECFS & #LongCovid patients can upload a genetics file & it will scan for genetic variants related to my hypothesis which I've developed further over the last year
me-cfs-genetic-analysis.base…
@lifeanalytics @DanMissailidis
1/10
Efthymios Kalafatis retweeted
Here is where you can register for this Thursday's PRIME symposium on post-exertional malaise: us02web.zoom.us/webinar/regi…
Efthymios Kalafatis retweeted
Thank you so much for inviting me to speak about our MAESTRO study @ngklimas @NSU_INIM!!! It was so great to get to speak with such an amazing group of clinicians, I'm inspired by all that you do!
Institute for Neuro-Immune Medicine: Decoding Infection-Associated Chronic Illness: The MAESTRO Study
'Dr. Michal Caspi Tal presents findings from the MAESTRO study (Measure Absolutely Everything So Tests can be Reliable and Objective)'
youtube.com/watch?v=QPUFuUJd…
Efthymios Kalafatis retweeted
We're currently in the process of making a website where you could upload a self-taken capillaroscopy image and get key features quantified. In the meantime if you want to send me a photo I can tell you what I see by eye, though my eyes are not as good as what we're building.
Efthymios Kalafatis retweeted
We're just about done with healthy volunteers but we still need a handful of people with pre-covid ME/CFS, and quite a few more people with Long COVID
This is for 1-200 people sized cohorts across multiple biological studies
Screening and contact form below👇(info not retained)
Still doing home visits for research into:
-platelet activation
-miRNAs
-cellular metabolism
-immune function
in pw/ ME/CFS or w/ Long COVID🩸🔬
If you're a woman with ME/CFS or Long COVID in VIC, Aus + want to be contacted, please fill in this form: redcap.latrobe.edu.au/redcap…
Efthymios Kalafatis retweeted
Read this #preprint on @researchsquare: Biological Insights from Genome-Wide Association Studies and Whole Genome Sequencing of Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome researchsquare.com/article/r…
Efthymios Kalafatis retweeted
1) 🇪🇸 A new Spanish study measured autoantibodies against adrenergic and muscarinic receptors in 59 patients with ME/CFS, 96 Long Covid and 36 healthy controls.
The results show a large overlap, questioning whether these antibodies are involved in ME/CFS pathology.
ALT Graph showing large overlap in adrenergic and muscarinic autoantibodies between ME/CFS patients, Long Covid patients, and healthy controls.
Efthymios Kalafatis retweeted
YESSS!!!! Congrats Chris Ponting and team
Great news from the UK🍾
£4.75 million to do whole-genome sequencing on 6000 DecodeME samples
thetimes.com/uk/healthcare/a…
(paywall)
Unfortunately it's not enough to analyse the full sample
People can find out more about SequenceME & donate here
megenetics.org.uk/our-projec…
#MEcfs #PwME
ALT Landmark ME study will map patients’ DNA in mission to find cure The government will provide £4.75 million in funding to British scientists who aim to create a test to reliably identify chronic fatigue syndrome new Maeve Boothby O’Neill died in 2021 from malnutrition caused by severe MEPA Oliver Wright, Policy Editor, and Kaya Burgess, Science Correspondent Monday May 11 2026, 10.15pm BST, The Times Listen • 4:24 min Share Prefer us on Google Thousands of patients suffering from chronic fatigue syndrome are to have their full genetic codes mapped in an attempt to find a cure for the debilitating and mysterious illness. The study, a world first for the syndrome also known as myalgic encephalomyelitis (ME), will be funded by an investment of £4.75 million from the government in the hope that it will lead to a test to reliably identify the illness and eventually develop drugs to treat it for the first time.
Efthymios Kalafatis retweeted
I want to ask you to follow this dot with your eyes. Was that easy? Without you even having to give that much thought, your brain is telling your eye muscles where to move to keep your focus on that dot. 1/
Efthymios Kalafatis retweeted
1/ I want to explain a bit about our MIT MAESTRO study. 🧵How can we help you get better if we don't know what's making you sick? If we don't currently have a way to identify what's going wrong, and we don't have the right tests, I think we need to MEASURE ABSOLUTELY EVERYTHING.
Efthymios Kalafatis retweeted
We are one person away from completing our sex and age matching for our MAESTRO study! One 56-65 year old male with long COVID who can come to MIT in person and this first chapter of MAESTRO will be complete!!!
Efthymios Kalafatis retweeted
Dozens of home visits already done in 2026 but we still need more people!
Please use the following link to determine if you are eligible for the study and if you agree for a member of our team to contact you: redcap.latrobe.edu.au/redcap…
🔬women in VIC, healthy OR w/ ME/CFS OR w/ LC
Efthymios Kalafatis retweeted
This thread is a must read if you want to understand what micro plastics are doing to your clean up crew tasked with taking out the garbage and also clearing out invading microorganisms.
Those who know me, know I’m not someone who changes his preferences & behaviors lightly. As Ron Swanson said, “I regret nothing. The end.” Well, let me tell you about our new study, out from @ThePerryLab @MSKCancerCenter in @ImmunityCP @CellPressNews, which is the exception. /1
